Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Azizi

Showing results (61-70 of 131) with videos related to

Pageof 14
Sort By:
Blood Pressure|April 21, 2017
Is it Possible to Differentiate between Angiotensin II Type 1 (AT1) Receptor Blockers in Normotensive Volunteers?M Azizi, G Chatellier, L Nicolet, et al.
Circulation|June 15, 1995
Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjectsM L Lachurié, M Azizi, T T Guyene, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|January 13, 2012
Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertensionM Azizi, O Steichen, M Frank, et al.
The Science of the Total Environment|September 4, 2025
Environmental assessment of potential toxic elements in the mining district of Mazarrón (SE, Spain)M Azizi, D M Carmona, A Faz, et al.
Revue Des Maladies Respiratoires|May 31, 2020
[Acute respiratory distress syndrome secondary to SARS-CoV-2 infection in an infant]M Lahfaoui, M Azizi, M Elbakkaoui, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 24, 1999
Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in ratsC Junot, L Nicolet, E Ezan, et al.
Presse Medicale (Paris, France : 1983)|October 15, 1994
[Therapeutic approach in arterial hypertension with renal artery stenosis]P F Plouin, G Chatellier, C Fumeron, et al.
Clinical Pharmacology and Therapeutics|May 1, 1999
Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humansC Massien, M Azizi, T T Guyene, et al.
European Journal of Pharmacology|January 9, 1999
The hemoregulatory peptide N-acetyl-ser-asp-lys-pro impairs angiotensin I-induced contractions in rat aortaC M Boulanger, E Ezan, F Massé, et al.
Hypertension (Dallas, Tex. : 1979)|March 19, 1999
Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humansM Azizi, E Ezan, J L Reny, et al.
Pageof 14

Showing results (61-70 of 131) with videos related to

Sort By:
Pageof 14
Blood Pressure|April 21, 2017
Is it Possible to Differentiate between Angiotensin II Type 1 (AT1) Receptor Blockers in Normotensive Volunteers?M Azizi, G Chatellier, L Nicolet, et al.
Circulation|June 15, 1995
Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjectsM L Lachurié, M Azizi, T T Guyene, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|January 13, 2012
Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertensionM Azizi, O Steichen, M Frank, et al.
The Science of the Total Environment|September 4, 2025
Environmental assessment of potential toxic elements in the mining district of Mazarrón (SE, Spain)M Azizi, D M Carmona, A Faz, et al.
Revue Des Maladies Respiratoires|May 31, 2020
[Acute respiratory distress syndrome secondary to SARS-CoV-2 infection in an infant]M Lahfaoui, M Azizi, M Elbakkaoui, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 24, 1999
Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in ratsC Junot, L Nicolet, E Ezan, et al.
Presse Medicale (Paris, France : 1983)|October 15, 1994
[Therapeutic approach in arterial hypertension with renal artery stenosis]P F Plouin, G Chatellier, C Fumeron, et al.
Clinical Pharmacology and Therapeutics|May 1, 1999
Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humansC Massien, M Azizi, T T Guyene, et al.
European Journal of Pharmacology|January 9, 1999
The hemoregulatory peptide N-acetyl-ser-asp-lys-pro impairs angiotensin I-induced contractions in rat aortaC M Boulanger, E Ezan, F Massé, et al.
Hypertension (Dallas, Tex. : 1979)|March 19, 1999
Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humansM Azizi, E Ezan, J L Reny, et al.
Pageof 14